(Total Views: 151)
Posted On: 07/19/2022 12:13:04 PM
Post# of 38429
$NBIO announced that the United States Patent and Trademark Office (the "USPTO"
has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab.
A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
The allowed patent application, which is titled, "KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS" (US Patent Application No. 17/515,010), provides broad protection for Pritumumab ("PTB" and the storage conditions related to its use in clinical applications.
Dr. Ivan Babic, in charge of Nascent's R&D, and the inventor listed on the patent, stated, "Allowance of the Pritumumab patent highlights the uniqueness of this naturally-derived antibody and the importance of the right experimental and storage conditions for maintaining its potency."
has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
The allowed patent application, which is titled, "KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS" (US Patent Application No. 17/515,010), provides broad protection for Pritumumab ("PTB"
and the storage conditions related to its use in clinical applications. Dr. Ivan Babic, in charge of Nascent's R&D, and the inventor listed on the patent, stated, "Allowance of the Pritumumab patent highlights the uniqueness of this naturally-derived antibody and the importance of the right experimental and storage conditions for maintaining its potency."
(0)
(0)
